We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients

By LabMedica International staff writers
Posted on 18 Mar 2024
Print article
Image: The DiaCarta RadTox Test is intended to offer an early assessment of patient response to treatment (Photo courtesy of DiaCarta)
Image: The DiaCarta RadTox Test is intended to offer an early assessment of patient response to treatment (Photo courtesy of DiaCarta)

The concentration of circulating cell-free DNA (cfDNA) in the bloodstream is an important indicator that can help track how well cancer treatments are working. Before starting treatment, measuring cfDNA levels can give doctors a snapshot of the extent of the cancer’s spread in the body. High levels of cfDNA often mean the cancer is widespread or aggressive. As treatment goes on, doctors can keep an eye on cfDNA levels to see if the treatment is effective. A drop in cfDNA levels could mean the treatment is working and the tumor is getting smaller. But if cfDNA levels remain unchanged or rise, it might mean the treatment isn't working, and the cancer is still growing or has become resistant to treatment. Now, a simple blood test monitors this liquid biomarker in real time to track how well a cancer treatment is working.

DiaCarta’s (Pleasanton, CA, USA) RadTox Test is a liquid biopsy test designed to monitor tumor response and progression by observing changes in cfDNA levels. This test is crucial for determining early on if a patient's treatment plan is effective, helping avoid unnecessary side effects. The RadTox Test uses DiaCarta's unique QuantiDNA Direct cfDNA Test technology to measure cfDNA concentrations in a blood sample without the need for sample purification. This method allows doctors to quickly assess how well a treatment is working. With this information, doctors can adjust treatments in a more accurately and timely manner than before.

The RadTox Test is particularly useful during various treatments, including radiation, chemotherapy, immunotherapy, and other cancer therapies, monitoring cfDNA levels throughout the entire course of treatment. This provides early insights into how the cancer is responding to treatment, well before imaging tests might show changes, often three months after therapy starts. This timely feedback is crucial for making informed treatment decisions. Unlike traditional molecular residual disease (MRD) monitoring that only look for specific cancer mutations after treatment, the RadTox Test offers a broader perspective by tracking overall cfDNA changes. This gives doctors a clearer understanding of the treatment's impact, helping tailor care to each patient's needs.

"With just 10 microliters of plasma, our test has generated significant clinical data across a broad spectrum of cancer treatments," explained Dr. Aiguo (Adam) Zhang, President, and CEO of DiaCarta. "Our initial findings across 22 tumor types with over 250,000 samples performed globally demonstrate the immense potential of this pan-cancer monitoring test."

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.